ClinicalTrials.gg
RecruitingNCT07725172Updated Nov 4, 2026

Radiation Therapy and Thymus Function in Young Women With Breast Cancer

An observational study in Breast Cancer, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Duke University · Observational

How we know

Updated Nov 4, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
125
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Breast Neoplasms by Duke University — 8 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Duke University.

Planned enrollment
2nd of 10
125 · median 61
Started
2026
with 6 others
Observational
10 of 69
1 open now
Registered
69th of 69
by date

Among the 69 studies in Breast Neoplasms by Duke University, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2026, is one of 10 observational ones, and was the 69th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 69 studies in Breast Neoplasms by Duke University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Breast Neoplasms by Duke University, or all of them as a file.
02

Study summary

Breast cancer treatment sometimes includes radiation to the breast or chest wall. There is a small gland, called the thymus, located in the upper chest that may receive a small amount of the radiation aimed at the breast. The goal of this study is to collect blood samples from young women with breast cancer to study the effect of radiation therapy on the thymus gland.

Read the detailed description

This study includes participants whose plan of care may or may not include radiation therapy.

  • Participants whose plan of care includes radiation therapy will have about three teaspoons of research blood collected at the following time points:

    • Before the start of radiation therapy
    • At the end of radiation therapy
    • About six months after completing radiation therapy
  • Participants whose plan of care does NOT include radiation therapy will have about three teaspoons of research blood collected at the following timepoints:

    • After surgery (up to three months after surgery)
    • About 8 months after the first research blood collection
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer in young women
  • blood collection
  • thymopoesis
  • thymus
  • radiation therapy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes women age 18-50 with breast cancer seen in the Duke Breast Oncology Program

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 50 undergoing mastectomy or breast-conserving surgery for breast cancer of any subtype at DUMC and associated satellite centers
  • Histologic documentation of breast cancer based on pathology
  • Systemic therapies including hormone therapy, targeted therapy, chemotherapy and immunotherapy as given for breast cancer treatment at the discretion of the treating medical oncologist are allowed and use of such therapies will be documented and included as a covariate
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Prior history of therapeutic high-dose irradiation of the thorax (e.g. for treatment of lung cancer, head/neck cancer, Hodgkin disease, etc., not just radiological imaging alone)
  • History of thymectomy or treatment with drugs within the past six months
  • Individuals with rheumatoid arthritis or other conditions
  • Individuals with Down's syndrome
  • Male patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Radiation Therapy

    Up to 100 Breast cancer patients receiving radiation therapy

    Procedure: Blood draw for the laboratory assessment

  • No Radiation Therapy

    Up to 25 Breast cancer patients NOT receiving radiation therapy as control

    Procedure: Blood draw for the laboratory assessment

Interventions

  • ProcedureBlood draw for the laboratory assessment

    Blood will be drawn and processed for Peripheral Blood Mononuclear Cells (PBMCs). PBMC biomarkers will be used to assess thymopoiesis .

06

What researchers measure

Primary outcomes

  1. Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells

    As measured by quantitative PCR in participants receiving radiotherapy (RT)

    Time frame: baseline

  2. Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells

    As measured by quantitative PCR in participants receiving radiotherapy (RT)

    Time frame: at the end of RT, about 5 weeks

  3. Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells

    As measured by quantitative PCR in participants receiving radiotherapy (RT)

    Time frame: 6 months post-RT

  4. Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells

    As measured by quantitative PCR in participants NOT receiving radiotherapy (RT)

    Time frame: within 3 months after breast cancer surgery

  5. Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells

    As measured by quantitative PCR in participants NOT receiving radiotherapy (RT)

    Time frame: approximately 8-11 months after breast cancer surgery

  6. Level of CD4+ recent thymic emigrant (RTE) cells in participant blood samples

    As measured by flow cytometry in blood from participants receiving radiotherapy (RT)

    Time frame: baseline

  7. Level of CD4+ RTE cells in participant blood samples

    As measured by flow cytometry in blood from participants receiving radiotherapy (RT)

    Time frame: at the end of RT, about 5 weeks

  8. Level of CD4+ RTE cells in participant blood samples

    As measured by flow cytometry in blood from participants receiving radiotherapy (RT)

    Time frame: 6 months post RT

  9. Level of CD4+ RTE cells in participant blood samples

    As measured by flow cytometry in blood from participants NOT receiving radiotherapy (RT)

    Time frame: within 3 months of breast cancer surgery

  10. Level of CD4+ RTE cells in participant blood samples

    As measured by flow cytometry in blood from participants NOT receiving radiotherapy (RT)

    Time frame: approximately 8-11 months after breast cancer surgery

  11. Effect of adjuvant radiotherapy treatment dose on levels of sjTREC-containing T cells

    using a linear mixed-effect model in participants receiving RT

    Time frame: 6 months post RT

  12. Effect of adjuvant radiotherapy treatment fractionation on levels of sjTREC-containing T cells

    using a linear mixed-effect model in participants receiving RT

    Time frame: 6 months post RT

  13. Effect of adjuvant radiotherapy treatment fractionation on levels of CD4+ RTE cells

    using a linear mixed-effect model in participants receiving RT

    Time frame: 6 months post RT

  14. Effect of adjuvant radiotherapy treatment dose on levels of CD4+ RTE cells

    using a linear mixed-effect model in participants receiving RT

    Time frame: 6 months post RT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — IPD may be shared after publication if deidentified.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 36 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Sep 2026 → Nov 2026, primary completion Sep 2029 → Nov 2029 and completion Sep 2029 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Nov 2029was Sep 2029
CompletionEst.
Nov 2029was Sep 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
Duke Cancer Center is now Recruiting
Sep 29, 2026
Start date
Sep 2026→Nov 2026
Nov 4, 2026
Primary completion
Sep 2029→Nov 2029
Nov 4, 2026
Study completion
Sep 2029→Nov 2029
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Sep 2026→Nov 2026
    Primary completion Sep 2029→Nov 2029
    Study completion Sep 2029→Nov 2029
    + 1 other change: verification date
  2. Sep 29, 2026
    Not yet recruiting→Recruiting
    Duke Cancer Center is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07725172
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Duke Radiation Oncology Clinical Trials
Contact
RadOnc-Clinical_Trials@dm.duke.edu
(919 668-3726
Susan McDuff, MD PhD
principal investigator · Duke University Health System (DUHS)
Andrew Macintyre, PhD
principal investigator · Duke Human Vaccine Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion